Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. ANET
3. NKE
4. BE
5. PANW
6. CL
7. SNDK
8. TAP
9. DELL
10. ROIV

Go back to Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 126.75 -1.25 (0.98%)
Previous Close $128.00    52 Week High $118.49 
Open $126.46    52 Week Low $55.00 
Day High $128.08    P/E N/A 
Day Low $126.04    EPS $-0.56 
Volume 1,036,074       

Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1149.36 -10.24 (0.88%)
Previous Close $1159.60    52 Week High $88.16 
Open $1150.61    52 Week Low $67.88 
Day High $1158.44    P/E 266.06 
Day Low $1138.31    EPS $4.32 
Volume 2,220,270